Overview

A Study to Assess the Effects of Canagliflozin (JNJ-28431754) on the Pharmacokinetics, Pharmacodynamics, and Safety of Glyburide in Healthy Volunteers

Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to determine how multiple doses of canagliflozin (JNJ-28431754) affect the pharmacokinetics (ie, how the body affects the drug) and pharmacodynamics (ie, how the drug affects the body) of a single dose of glyburide.
Phase:
Phase 1
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Treatments:
Canagliflozin
Glyburide
Criteria
Inclusion Criteria:

- Volunteer must have a body mass index (BMI = weight in kg/height in m2) between 18 and
30 kg/m2 (inclusive) and body weight not less than 50 kg Exclusion Criteria:

- Volunteer has a history of or currently active illness considered to be clinically
significant by the Investigator or any other illness that the Investigator considers
should exclude the patient from the study or that could interfere with the
interpretation of the study results

- Volunteer has a fasting plasma glucose < 100 mg/dL (as measured by oral glucose
tolerance test) and a 2-hour plasma glucose <= 140 mg/dL

- History of smoking or use of nicotine-containing substances within the previous 6
months